Evidence map›Paper›PMID 33106805›Full record

ArticlebioRxiv : the preprint server for biology2021

Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity.

Linh T Bui, Nichelle I Winters, Mei-I Chung, Chitra Joseph, Austin J Gutierrez, Arun C Habermann, Taylor S Adams, Jonas C Schupp, Sergio Poli, Lance M Peter and 12 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 2 countries.

Linh T BuiTranslational Genomics Research Institute, Phoenix, AZ, USA.
Nichelle I WintersDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Mei-I ChungTranslational Genomics Research Institute, Phoenix, AZ, USA.
Chitra JosephRespiratory Medicine NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Austin J GutierrezTranslational Genomics Research Institute, Phoenix, AZ, USA.
Arun C HabermannDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Taylor S AdamsSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Jonas C SchuppSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Sergio PoliDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lance M PeterTranslational Genomics Research Institute, Phoenix, AZ, USA.
Chase J TaylorDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Jessica B BlackburnDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Bradley W RichmondDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Andrew G NicholsonNational Heart and Lung Institute, Imperial College, London, SW3 6LY, UK.
Doris RasslPathology Research, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
William A WallaceDepartment of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Ivan O RosasPulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
R Gisli JenkinsRespiratory Medicine NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Naftali KaminskiSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Jonathan A KropskiDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Nicholas E BanovichTranslational Genomics Research Institute, Phoenix, AZ, USA.
Human Cell Atlas Lung Biological Network
Translational Genomics Research Institute · USVanderbilt University Medical Center · USYale University · USUniversity of Nottingham · GBBaylor College of Medicine · USBrigham and Women's Hospital · USEdinburgh Royal Infirmary · GBPapworth Hospital NHS Foundation Trust · GBRoyal Brompton & Harefield NHS Foundation Trust · GBVanderbilt University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Interdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3M
Spatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0M
Genomic Analysis of Tissue and Cellular Heterogeneity in IPFR01HL127349 · NHLBI · YALE UNIVERSITY · PI BENOS, PANAGIOTIS V, KAMINSKI, NAFTALI · 2015 to 2025
$5.9M
Epithelial Protective Effects of Thyroid Hormone Signaling in FibrosisR01HL141852 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$3.4M
Normal Aging Lung Cell Atlas (NALCA)U01HL145567 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$2.8M
Mir-29 mimicry as a therapy for pulmonary fibrosisUH2HL123886 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2014 to 2015
$2.7M
Role of p73 in COPD PathogenesisIK2BX003841 · VA · VETERANS HEALTH ADMINISTRATION · PI RICHMOND, BRADLEY WINSTON · 2019 to 2023
–
BLRD VA IK2 BX003841Medical Research Council G0901226NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL127349NHLBI NIH HHS R01 HL141852NHLBI NIH HHS R01 HL145372NHLBI NIH HHS T32 HL094296NHLBI NIH HHS U01 HL145567NHLBI NIH HHS UH2 HL123886
6 · The paper itself

Abstract

Patients with chronic lung disease (CLD) have an increased risk for severe coronavirus disease-19 (COVID-19) and poor outcomes. Here, we analyzed the transcriptomes of 605,904 single cells isolated from healthy and CLD lungs to identify molecular characteristics of lung cells that may account for worse COVID-19 outcomes in patients with chronic lung diseases. We observed a similar cellular distribution and relative expression of SARS-CoV-2 entry factors in control and CLD lungs. CLD epithelial cells expressed higher levels of genes linked directly to the efficiency of viral replication and innate immune response. Additionally, we identified basal differences in inflammatory gene expression programs that highlight how CLD alters the inflammatory microenvironment encountered upon viral exposure to the peripheral lung. Our study indicates that CLD is accompanied by changes in cell-type-specific gene expression programs that prime the lung epithelium for and influence the innate and adaptive immune responses to SARS-CoV-2 infection.

Indexed as

COPDCOVID-19genomicspulmonary fibrosisscRNA-seq

Identifiers

PMID33106805
PMCPMC7587778
OpenAlexW3118309683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.